Fig. 4: Treated CD4 + T cells with or without BRM014 for 10 h.
From: Acute depletion of BRG1 reveals its primary function as an activator of transcription
a. A snapshot from the genome browser, showing Pro-seq data for both WT (represented by two replicates in blue) and BRM014 (indicated by two replicates in red). b MA plot shows PRO-seq derived changes in nascent transcription in T cells after 12-h BRM014 treatment. Blue and red dots represent genes with significant increases and decreases in expression, respectively, with a dashed line for no change. Significance was determined by a two-sided ROTS test using P < 0.05 and fold-change > 1.3 criteria for differential expression. c A snapshot from the genome browser, showing DNase-seq data for both WT (represented by two replicates in blue) and BRM014 (indicated by two replicates in red). d A volcano plot displays DNase-seq density changes at DHSs after 12-h BRM014 treatment. Blue and red dots show significant increases and decreases, respectively; the dashed line marks no change. DHSs were selected based on P < 0.05 and fold-change > 1.3, using a two-sided ROTS analysis. e A heatmap shows DNase-seq read density at DHSs for both BRG1-depleted samples and samples with a 12-h treatment with the BRM014 inhibitor. The DHSs are separated into three groups (decreased, increased, and unchanged) based on the changes in DNase-seq read density upon BRG1-depletion (AID versus WT).
